Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Part of paid clinical trials in Anniston, Alabama.
- Sponsor
- Kailera
- Study ID
- NCT07284875
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KAI-9531 — DRUGSC Injection
- Placebo — DRUGSC Injection
Study Details
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Key Dates
- Start date
- Dec 18, 2025
- Status verified
- Jun 2026
- Primary completion
- Feb 28, 2028
- Completion
- Mar 27, 2028
Study Design
- Enrollment
- 1,800 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: KAI-9531: Dose 1Participants will receive Dose 1 of KAI-9531 once weekly.
- Experimental: KAI-9531: Dose 2Participants will receive Dose 2 of KAI-9531 once weekly.
- Experimental: KAI-9531: Dose 3Participants will receive Dose 3 of KAI-9531 once weekly.
- Experimental: KAI-9531: Dose 4Participants will receive Dose 4 of KAI-9531 once weekly.
- Placebo Comparator: PlaceboParticipants will receive placebo matched to KAI-9531 once weekly.
Primary Outcome Measure
Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76 [ Time Frame: Baseline, Week 76 ]
Central Contacts
- Kailera Therapeutics, Inc.781-317-0291
Locations (23)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Kailera Clinical Site | Anniston | Alabama | 36207 | - |
| Kailera Clinical Site | Birmingham | Alabama | 35294 | - |
| Kailera Clinical Site | Cullman | Alabama | 35055 | - |
| Kailera Clinical Site | Sun City | Arizona | 85351 | - |
| Kailera Clinical Site | Escondido | California | 92025 | - |
| Kailera Clinical Site | Toluca Lake | California | 91602 | - |
| Kailera Clinical Site | Aurora | Colorado | 80012 | - |
| Kailera Clinical Site | Bridgeport | Connecticut | 06606 | - |
| Kailera Clinical Site | Jupiter | Florida | 33458 | - |
| Kailera Clinical Site | Lilburn | Georgia | 30047 | - |
| Kailera Clinical Site | Springfield | Illinois | 62072 | - |
| Kailera Clinical Site | Columbia | Maryland | 21045 | - |
| Kailera Clinical Site | Las Vegas | Nevada | 89119 | - |
| Kailera Clinical Site | Rochester | New York | 14609 | - |
| Kailera Clinical Site | Morehead City | North Carolina | 28557 | - |
| Kailera Clinical Site | Chickasha | Oklahoma | 73018 | - |
| Kailera Clinical Site | Mauldin | South Carolina | 29662 | - |
| Kailera Clinical Site | Chattanooga | Tennessee | 37405 | - |
| Kailera Clinical Site | Amarillo | Texas | 79124 | - |
| Kailera Clinical Site | DeSoto | Texas | 75115 | - |
| Kailera Clinical Site | Tomball | Texas | 77375 | - |
| Kailera Clinical Site | Salt Lake City | Utah | 84124 | - |
| Kailera Clinical Site | Danville | Virginia | 24541 | - |
Find similar trials in Anniston, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia